Zydus Lifesciences Reports 22 Percent Revenue Growth in Q1 FY27, Advances Innovation Pipeline
Zydus Lifesciences began FY27 with strong double-digit growth, driven by robust performance across India and international formulations, alongside continued progress in manufacturing quality and biosimilar innovation.
GMP Surveillance | 12/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy